Brief Report: Attention Deficit and Hyperactivity Disorder Scores Are Elevated and Respond toN-Acetylcysteine Treatment in Patients With Systemic Lupus Erythematosus

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial

(2012) Zhi-Wei Lai et al.   ARTHRITIS AND RHEUMATISM

Adult Psychiatric Outcomes of Girls With Attention Deficit Hyperactivity Disorder: 11-Year Follow-Up in a Longitudinal Case-Control Study

(2010) Joseph Biederman et al.   AMERICAN JOURNAL OF PSYCHIATRY

A Comparison of the Efficacy of Medications for Adult Attention-Deficit/Hyperactivity Disorder Using Meta-Analysis of Effect Sizes

(2010) Stephen V. Faraone et al.   JOURNAL OF CLINICAL PSYCHIATRY

Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial

(2009) Michelle Bernardo et al.   ACTA NEUROPSYCHIATRICA

Pharmacotherapy of systemic lupus erythematosus

(2009) Lisa Francis et al.   EXPERT OPINION ON PHARMACOTHERAPY

N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial

(2008) Michael Berk et al.   BIOLOGICAL PSYCHIATRY